In the Media

November 1, 2018

Video: InMed CEO Eric A. Adams – how InMed is different from competitors

In this video, InMed CEO Eric A. Adams talks about how InMed is differentiated from competitors.

InMed does not grow cannabis. We biosynthesize the compounds in a lab.
InMed products do not contain THC.
InMed products are applied topically.

Source: BTV

Share this post

Latest Articles

Benzinga: Pharmaceutical Cannabinoids and their Impact on Treatments for Complex Diseases

InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, join the Benzinga Small Cap Conference Panel Discussion “Pharmaceutical Cannabinoids and their Impact on Treatments

October 6, 2021

The Dales Report – InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off”

Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids.

September 22, 2021

InMed and BayMedica Host First Webinar Together Following News of Signing Definitive Agreement on Acquisition

InMed and BayMedica hosted a live webinar to talk about InMed’s acquisition of BayMedica, how it positions the company as a leader in the manufacturing

September 16, 2021